BRIEF: 111 Inc.’s revenue drops in second quarter
Drug seller 111 Inc. (YI.US) said on Wednesday its revenue fell 6.4% year-on-year to 3.2 billion yuan ($450 million) in the second quarter, as revenue for its core business of selling drugs to pharmacies and medical institutions fell by 6.2%. Its much smaller business of selling drugs directly to consumers also fell 9.6% for the quarter year-on-year.
The company’s operating costs and expenses fell by a similar 6.3% to 3.2 billion yuan from 3.4 billion yuan in the year-ago period. As a result, 111 Inc. reported positive income from operations of $100,000 for the quarter. But its net loss widened to 19.5 million yuan from 14 million yuan a year earlier.
The company’s shares fell 6.2% on Wednesday after the report’s publication. The stock is down 40% over the last six months.
By Doug Young
To subscribe to Bamboo Works free weekly newsletter, click here
Related Articles
RELATED ARTICLES
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK -
BRIEF: Sands China second-quarter profit drops 13%
1928.HK
-
Second-quarter box office blues dampen diversifying Maoyan
1896.HK
-
BRIEF: Legend Biotech’s revenue rises 36% in second quarter
LEGN.US
-
BRIEF: NetEase revenue, profit rise in second quarter
9999.HK NTES.US
- RNA drug developer Ribo Life targets fresh funding channel
-
Investors cheer Akeso’s revenue milestone, even as it returns to the red
9926.HK
